Modulation of ghrelin axis influences the growth of colonic and prostatic cancer cells in vitro

Pharmacological Reports

Volumn 64, Issue 4, 2012, Pages 951-959

  Ławnicka, Hanna ^a   Mełeń Mucha, Gabriela ^a   Motylewska, Ewelina ^a   Mucha, Sławomir ^a   Stȩpień, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Colon and prostate cancer cell line; Ghrelin; Ghrelin receptor antagonist

Indexed keywords

ACYLATED GHRELIN; FLUOROURACIL; GHRELIN; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; UNACYLATED GHRELIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; COLORIMETRY; CONCENTRATION RESPONSE; CYTOSTASIS; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER;

EID: 84867689694     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70890-3     Document Type: Article

References (44)

1. Barzon L, Pacenti M, Masi G, Stefani AL, Fincati K, Palù G.: Loss of growth hormone secretagogue receptor 1a and overexpression of type 1b receptor transcripts in human adrenocortical tumors. Oncology, 2005, 68, 414-421. (Pubitemid 41160972)
2. Broglio F, Gottero C, Benso A, Prodam F, Destefanis S, Gauna C, Maccario M et al.: Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans. J Endocrinol Invest, 2003, 26, 192-196. (Pubitemid 36681737)
3. Bustin SA, Jenkins PJ: The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends Mol Med, 2001, 7, 447-454. (Pubitemid 32964159)
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 2003, 348, 1625-1638. (Pubitemid 36459468)
5. Cassoni P, Ghé C, Marrocco T, Tarabra E, Allia E, Catapano F, Deghenghi R et al.: Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol, 2004, 150, 173-184. (Pubitemid 38312810)
6. Cassoni P, Papotti M, Ghè C, Catapano F, Sapino A, Graziani A, Deghenghi R et al.: Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab, 2001, 86, 1738-1745. (Pubitemid 32374931)
7. Cooperberg MR, Broering JM, Litwin MS: The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol, 2004, 171, 1393-1401. (Pubitemid 38365382)
8. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res, 1975, 35, 2434-2439.
9. Cowey SL, Quast M, Belalcazar LM, Wei J, Deng X, Given R, Singh P: Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression. Cancer, 2005, 103, 2643-2653. (Pubitemid 40800546)
10. De Angelis PM, Svendsrud DH, Kravik KL, Stokke T: Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer, 2006, 5, 20-21.
11. Dixit VD, Weeraratna AT, Yang H, Bertak D, Cooper-Jenkins A, Riggins GJ, Eberhart CG, Taub DD: Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in astrocytoma motility. J Biol Chem, 2006, 281, 16681-16690.
12. Duxbury MS, Waseem T, Ito H, Robinson MK, Zinner MJ, Ashley SW, Whang EE: Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem Biophys Res Commun, 2003, 309, 464-468. (Pubitemid 37025913)
13. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer, 2001, 1, 34-45. (Pubitemid 33741879)
14. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E et al.: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res, 2001, 7, 1888-1893. (Pubitemid 32994822)
15. Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Cox MC et al.: A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol, 2005, 173, 790-796. (Pubitemid 40239343)
16. Freeman HJ: Risk of gastrointestinal malignancies and mechanisms of cancer development with obesity and its treatment. Best Pract Res Clin Gastroenterol, 2004, 18, 1167-1175.
17. Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, Cunningham GR: Hypogonadism in male patients with cancer. Cancer, 2006, 106, 2583-2591.
18. He XT, Fan XM, Zha XL: Ghrelin inhibits 5-fluorouracil-induced apoptosis in colonic cancer cells. J Gastroenterol Hepatol, 2011, 26, 1169-1173.
19. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004, 350, 2335-2342. (Pubitemid 38702844)
20. Jeffery PL, Herington AC, Chopin LK: Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol, 2002, 172, R7-11.
21. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, Han BH et al.: Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone, 2005, 37, 359-369. (Pubitemid 41160494)
22. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth hormone releasing acylated peptide from stomach. Nature, 1999, 402, 656-660. (Pubitemid 129516334)
23. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB: Ghrelin - a hormone with multiple functions. Front Neuroendocrinol, 2004, 25, 27-68. (Pubitemid 38737393)
24. Lanfranco F, Baldi M, Cassoni P, Bosco M, Ghé C, Muccioli G: Ghrelin and prostate cancer. Vitam Horm, 2008, 77, 301-324.
25. Mełeń-Mucha G: Effects of short term treatment with pentagastrin, proglumide, tamoxifen given separately or together with 5-fluorouracil on the growth in the murine transplantable Colon 38 cancer. Neoplasma, 2001, 48, 134-139.
26. Mełeń-Mucha G: The combined effects of tamoxifen or proglumide with 5-fluorouracil on the growth of murine transplantable Colon 38 cancer. GI Cancer, 2001, 3, 383-394.
27. Mełeń-Mucha G, Ławnicka H: Leptin promotes the growth of Colon 38 cancer cells and interferes with the cytotoxic effect of fluorouracil in vitro. Endokrynol Pol, 2007, 58, 2-6.
28. Mełeń-Mucha G, Winczyk K, Pawlikowski M: Effects of somatostatin analogs octreotide and lanreotide on the proliferation and apoptosis in Colon 38 tumor: interaction with 5-fluorouracil. Neuroendocrinol Lett, 2000, 21, 137-142. (Pubitemid 30201157)
29. Mełeń-Mucha G, Winczyk K, Pawlikowski M: Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine Colon 38 cancer. Anticancer Res, 1998, 18, 3615-3620.
30. Miyake H, Chi KN, Gleave ME: Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgenindependent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res, 2000, 6, 1655-1663. (Pubitemid 30305057)
31. Motylewska E, Mełeń-Mucha G: Estrone and progesterone inhibit the growth of murine MC38 colon cancer line. J Steroid Biochem Mol Biol, 2009, 113, 75-79.
32. Motylewska E, Stasikowska O, Mełeń-Mucha G: The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line. Cancer Lett, 2009, 276, 68-73.
33. Pluta K, Jeleń M, Morak-Młodawska B, Zimecki M, Artym J, Kociȩba M: Anticancer activity of newly synthesized azaphenothiazines from NCI's anticancer screening bank. Pharmacol Rep, 2010, 62, 319-332.
34. Renehan AG, Soerjomataram I, Leitzmann MF: Interpreting the epidemiological evidence linking obesity and cancer: A framework for population-attributable risk estimations in Europe. Eur J Cancer, 2010, 46, 2581-2592.
35. Saltz L: Drug treatment of colorectal cancer. Drugs, 1991, 42, 616-627.
36. Schrag D: The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med, 2004, 351, 317-319.
37. Smith JP, Stock EA, Wotring MG, McLaughlin PJ, Zagon IS: Characterization of the CCK-B/gastrin-like receptor in human colon cancer. Am J Physiol, 1996, 271, R797-805.
38. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer, 1978, 21, 274-281. (Pubitemid 8283045)
39. Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, Szende B et al.: Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer, 2000, 82, 1724-1731. (Pubitemid 30229585)
40. Thompson NM, Gill DA, Davies R, Loveridge N, Houston PA, Robinson IC, Wells T: Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology, 2004, 145, 234-242. (Pubitemid 38202164)
41. Wang W, Andersson M, Iresjö BM, Lönnroth C, Lundholm K: Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int J Oncol, 2006, 28, 1393-1400.
42. Williams H, Powell IJ: Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol, 2009, 472, 439-453.
43. Wingo PA, Tong T, Bolden S: Cancer statistics. CA Cancer J Clin, 1995, 45, 8-30.
44. Yeh AH, Jeffery PL, Duncan RP, Herington AC, Chopin LK: Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin Cancer Res, 2005, 11, 8295-8303. (Pubitemid 41746940)